MedTrace Logo

A Study to Evaluate the Efficacy and Safety of VCT220 in Obesity Chinese Population

NCT06569355 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2025-07-01

No results posted yet for this study

Summary

The goal of the study is to assess how VCT220 tablets affect the bodyweight when used once daily in obese or overweight adult participants

Qualified participants will be randomly assigned to one of four groups using a computerized system. Participants will get VCT220 or placebo tablets for 16 weeks and will need to take tablets each morning.

Participants will have 7 clinic visits and a final follow-up visit approximately 14 days after the last study intervention administration.

Conditions

Interventions

DRUG

VCT220

A small molecule GLP-1R agonist tablet, orally administration, once daily

DRUG

Placebo

Placebo tablet

Sponsors & Collaborators

  • Vincentage Pharma Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-27
Primary Completion
2024-07-13
Completion
2024-08-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06569355 on ClinicalTrials.gov